Jane Street’s Cartesian Therapeutics RNAC Stock Holding History

Jane Street’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,100	Closed	-$138K	–	12780
2025 Q4	$138K	Buy	+19,100	New	+$154K	﹤0.01%	9995

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street's RNAC Position: Q2 2024 in Review

Jane Street sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 6,340 shares — an estimated $124K sold.

Jane Street first reported a position in RNAC in Q2 2019 and held it in 15 quarters. The position peaked at $478K in Q2 2020. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

Jane Street reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
Jane Street sold 6,340 Cartesian Therapeutics shares in Q2 2024, an estimated $124K.
Jane Street first reported a position in Cartesian Therapeutics in Q2 2019 and held it in 15 quarters.
Jane Street's Cartesian Therapeutics position peaked at $478K in Q2 2020.
61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Jane Street's 13F filing for Q2 2024, filed 15 Aug 2024.